The science behind
every biotech bet
PhD-reviewed pipeline analysis, clinical trial scoring, and risk-adjusted valuations. Built for investors who read the data, not just the headlines.
Aggregating data from
Deep analysis on the biotech
companies that matter
Click any company to explore pipeline data, financials, ownership, catalysts, and more.
Five dimensions.
One score.
Every company is automatically scored across five weighted dimensions derived from peer-reviewed frameworks in drug development and biotech valuation. AI-powered analysis of clinical trials, FDA data, financials, and more.
Target validation, MOA novelty, IP/patent strength, preclinical data quality
Trial design rigor (Keegan's 5 Pillars), endpoint quality, statistical significance, safety
Data completeness, reproducibility, what's NOT reported (red flags), submission readiness
Market position, pipeline diversity, partnership quality, peak sales potential
FDA pathway/designation, indication success probability, PDUFA timeline, label breadth
Every trial. Every phase.
Every risk quantified.
We pull every registered clinical trial from ClinicalTrials.gov, cross-reference with FDA drug applications, and map each compound through our probability-adjusted pipeline model based on indication-specific success rates.
Cash runway is survival.
We track every dollar.
10-year historical financials, dilution tracking, burn rate projections, and R&D intensity analysis. Biotech-specific metrics that generic screeners miss — because a Phase 3 biotech burning $400M/quarter isn't the same as a SaaS company.
Know the dates
that move the stock.
PDUFA dates, data readouts, conference presentations, and patent cliffs — mapped to a timeline so you never miss a binary event. Each catalyst is rated by expected magnitude and direction.
Built on published research,
not blog posts.
Our analytical framework is grounded in three foundational texts on biotech valuation and drug development.
Biotechnology Valuation
Phase transition probabilities, rNPV methodology, indication-specific success rates
Legal Guide to Biotech
Deal economics, licensing structures, IP portfolio analysis, regulatory pathways
IP Valuation in Pharma
Patent valuation methods, freedom-to-operate analysis, IP lifecycle mapping
The conviction to invest
starts with the data to
understand the science.
Join investors who evaluate biotech companies with the same rigor the FDA uses to review them.
Get our free daily biotech digest — AI-scored news, catalyst alerts, and pipeline updates.